Adva Kochavi

Adva Kochavi

Auto-generated profile, based on publicly available information

Adva Kochavi

The Netherlands Cancer Institute 1 Division of Oncogenomics, Oncode Institute Amsterdam, the Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2024 in Science
Verified
Journal Article
Closed access
NBNicolaas J. Boon
Nicolaas J. Boon
RORafaela A. Oliveira
Rafaela A. Oliveira
PKPierré-René Körner
Pierré-René Körner
AKAdva Kochavi
Adva Kochavi
SMSander Mertens
Sander Mertens
TBThijn R. Brummelkamp
Thijn R. Brummelkamp
In response to excessive DNA damage, human cells can activate p53 to induce apoptosis. Cells lacking p53 can still undergo apoptosis upon DNA damage, yet the responsible pathways are unknown. We observed that p53-independent apoptosis in response to DNA damage coincided with translation inhibition, which was characterized by ribosome stalling on rare leucine-encoding UUA codons and globally curtailed translation initiation. A genetic screen identified the transfer RNAse SLFN11 and the kinase GCN2 as factors required for UUA stalling and global translation inhibition, respectively. Stalled ribosomes activated a ribotoxic stress signal conveyed by the ribosome sensor ZAKα to the apoptosis machinery. These results provide an explanation for the frequent inactivation of SLFN11 in chemotherapy-unresponsive tumors and highlight ribosome stalling as a signaling event affecting cell fate in response to DNA damage.

2 June 2026 in Cancer Research
Verified
Journal Article
Open access
RNRemco Nagel
Remco Nagel
AKAdva Kochavi
Adva Kochavi
KFKarine Flem-Karlsen
Karine Flem-Karlsen
MAMrittika Adhikary
Mrittika Adhikary
YGYali Gal-On
Yali Gal-On
RAReuven Agami
Reuven Agami
Arginine biosynthesis is frequently suppressed in cancer because of the loss of argininosuccinate synthase 1 (ASS1) expression, rendering cancer cells reliant on extracellular arginine. This feature has driven the development of systemic arginine-depleting strategies, which are clinically safe but offer limited clinical benefit. In this study, we demonstrated that under arginine scarcity, cancer cells with low ASS1 expression resort to aberrant mRNA translation, characterized by ribosomal frameshifts and amino acid misincorporations. Although aberrant proteins originated from most arginine codons, the predominant effect was observed at AGA. This codon preference was caused by a selective decrease in tRNAArg (UCU) levels following arginine deprivation, linked to methyltransferase-like 1 (METTL1)–mediated tRNA modification. Proteomics and immunopeptidomics analyses validated that arginine shortage induced aberrant protein production at the endogenous level. T-cell receptor (TCR) T cells that specifically recognize these HLA-presented mistranslated peptides efficiently killed cancer cells after arginine deprivation. These results lay the foundation for improved cancer therapies by combining systemic arginine-depleting strategies with TCR-based targeting of nonclassical neoantigens. Significance: Aberrant protein production induced by arginine deprivation in ASS1-low cancers leads to production of neoantigens that represent promising targets for TCR-T cell therapies.